+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05335928

Evaluating Abatacept Versus Placebo for Immune Checkpoint Inhibitor-Related Myocarditis A Randomized, Double-Blind Study of Abatacept Plus Standard Care in Hospitalized Patients

Led by Massachusetts General Hospital · Updated on 2026-08-20

390

Participants Needed

31

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating whether abatacept, compared to a placebo, can reduce major adverse cardiac events MACE in patients hospitalized with myocarditis caused by immune checkpoint inhibitors ICI. This condition is a rare but serious side effect of ICI cancer treatments, and current corticosteroid therapies still result in a high rate of cardiac complications. The trial aims to provide clearer evidence on abatacepts potential benefits in this setting through a randomized, double-blind, placebo-controlled phase 3 study. Participants receive up to four intravenous doses of abatacept at 10 mgkg or placebo, given at randomization, 24 hours later, at 14 days, and optionally at 28 days. All participants continue standard care including corticosteroids. The study compares abatacept plus standard care with placebo plus standard care. The trial is conducted with careful monitoring of cardiac events and safety outcomes over six months. During the study, participants are hospitalized at randomization and undergo regular assessments including monitoring of heart function, blood tests for markers like troponin, and clinical status evaluations. The main outcome is the occurrence of major cardiac events within six months. Secondary measures include illness severity scales, additional cardiac markers, and immune-related side effects. The study also tracks adverse events and overall patient health throughout the trial period.

CONDITIONS

Brief Title

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Research Team

H

Hannah K Gilman, MS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here